MCID: NRG002
MIFTS: 53

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 28 14
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 41
Neurogenic Urinary Bladder 69
Neuropathic Bladder 12
Bladder Neurogenic 51

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 34 596.54
MeSH 41 D001750
NCIt 46 C79696
UMLS 69 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to urofacial syndrome 1 and lethal congenital contracture syndrome 2, and has symptoms including neuromuscular manifestations, neurobehavioral manifestations and urgency of micturition. An important gene associated with Neurogenic Bladder is EBF3 (Early B Cell Factor 3), and among its related pathways/superpathways are Calcium signaling pathway and Arf6 trafficking events. The drugs Acetylcholine and Oxybutynin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, prostate and testes, and related phenotypes are cardiovascular system and integument

Wikipedia : 72 Neurogenic bladder dysfunction, sometimes simply referred to as neurogenic bladder, is a dysfunction of... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 urofacial syndrome 1 32.1 HPSE2 LRIG2
2 lethal congenital contracture syndrome 2 31.7 ERBB3 PIP5K1C
3 bladder disease 29.5 P2RX2 TRPV1
4 hinman syndrome 11.5
5 polyglucosan body neuropathy, adult form 11.1
6 adult polyglucosan body disease 11.1
7 lethal congenital contracture syndrome 3 11.0
8 peroxisome biogenesis disorder 10b 11.0
9 spinal cord injury 10.5
10 vesicoureteral reflux 1 10.3
11 multiple sclerosis 10.3
12 myelomeningocele 10.3
13 bacteriuria 10.3
14 neural tube defects 10.2
15 urethritis 10.2
16 prostatitis 10.1
17 cystitis 10.0
18 bladder cancer 10.0
19 cerebritis 10.0
20 herpes zoster 10.0
21 cerebral palsy 9.9
22 cervicitis 9.9
23 spasticity 9.9
24 low compliance bladder 9.9 P2RX1 P2RX2
25 hyperreflexia 9.8
26 systemic lupus erythematosus 9.8
27 aging 9.8
28 prostatic hyperplasia, benign 9.8
29 anxiety 9.8
30 arthrogryposis multiplex congenita, neurogenic, with myelin defect 9.8
31 chronic kidney failure 9.8
32 prostatic hypertrophy 9.8
33 pyelonephritis 9.8
34 neurogenic bowel 9.8
35 bladder neck obstruction 9.8
36 interstitial cystitis 9.8
37 perinephritis 9.8
38 kidney disease 9.8
39 neuronitis 9.8
40 lupus erythematosus 9.8
41 blood group, i system 9.7
42 fibrosis of extraocular muscles, congenital, 1 9.7
43 multiple system atrophy 1 9.7
44 myelopathy, htlv-1-associated 9.7
45 pelvic organ prolapse 9.7
46 down syndrome 9.7
47 myeloma, multiple 9.7
48 supranuclear palsy, progressive, 1 9.7
49 legionnaire disease 9.7
50 corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia 9.7

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Ischemic Heart Disease
Multiple Sclerosis Osteoporosis
Paralytic Ileus Paraplegia
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Prostatic Hypertrophy Protein-Energy Malnutrition
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


neuromuscular manifestations, neurobehavioral manifestations, urgency of micturition, vertigo, seizures, reflex, abnormal, pain, meningism, dysuria

MGI Mouse Phenotypes related to Neurogenic Bladder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 CHRM2 ERBB3 GBE1 P2RX1 P2RX2 PIP5K1C
2 integument MP:0010771 9.43 CHRM2 ERBB3 LRIG2 PEX3 PIP5K1C TRPV1
3 nervous system MP:0003631 9.23 CHRM2 EBF3 ERBB3 GBE1 LRIG2 P2RX2

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
2
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2 5633-20-5 4634
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Sulfamethoxazole Approved Phase 4,Phase 1,Phase 2 723-46-6 5329
5
Trimethoprim Approved, Vet_approved Phase 4,Phase 1,Phase 2 738-70-5 5578
6
Silodosin Approved Phase 4 160970-54-7
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
8
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10 abobotulinumtoxinA Phase 4,Phase 3,Phase 2
11 Botulinum Toxins Phase 4,Phase 3,Phase 2
12 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2
13 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Neuromuscular Agents Phase 4,Phase 3,Phase 2
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
16 onabotulinumtoxinA Phase 4,Phase 3,Phase 2
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
18 Anesthetics Phase 4
19 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
21 Adrenergic alpha-Antagonists Phase 4,Phase 2,Phase 3,Phase 1
22 Adrenergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
24 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antitubercular Agents Phase 4,Phase 1,Phase 2
27 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Clavulanic Acid Phase 4
29 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Parasympatholytics Phase 4,Phase 3,Phase 2
32 Autonomic Agents Phase 4,Phase 3,Phase 2
33 Mandelic Acids Phase 4,Phase 3,Phase 2
34 Solifenacin succinate Phase 4 242478-38-2
35
Tamsulosin Approved, Investigational Phase 2, Phase 3,Phase 1 106133-20-4 129211
36
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
37
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
38
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
39
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
40
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
41
Ofloxacin Approved Phase 3 82419-36-1 4583
42
Fesoterodine Approved Phase 3 286930-02-7, 286930-03-8 6918558
43 Mirabegron Approved Phase 2, Phase 3 223673-61-8
44
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
45 Cranberry Approved, Investigational, Nutraceutical Phase 3
46 tannic acid Approved, Nutraceutical Phase 2, Phase 3
47 Octenidine Investigational Phase 2, Phase 3 71251-02-0
48 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
49 Pharmaceutical Solutions Phase 3,Phase 1
50 Antioxidants Phase 3

Interventional clinical trials:

(show top 50) (show all 83)

# Name Status NCT ID Phase Drugs
1 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
3 Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
4 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
5 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
6 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
7 Quality of Life Intermittent Catheter Study Completed NCT01523743 Phase 4
8 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
9 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome Completed NCT00277563 Phase 4
10 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder Recruiting NCT01192568 Phase 4 Oxybutynin
11 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
12 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
13 Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
14 Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
15 Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction Completed NCT00549939 Phase 3 Alfuzosin;Placebo
16 Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology Completed NCT00576823 Phase 3 Alfuzosin
17 Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
18 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
19 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
20 Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
21 Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients Completed NCT00280592 Phase 3 Cranberry;Placebo
22 A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Completed NCT00258089 Phase 3 Levofloxacin
23 A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Recruiting NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
24 Antiseptic-coated Intermittent Urinary Catheter Not yet recruiting NCT02697162 Phase 2, Phase 3 Octenidine chloride
25 Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
26 Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) Unknown status NCT02591901 Phase 2 Uro vaxom
27 Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
28 Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Unknown status NCT01305681 Phase 1, Phase 2
29 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
30 PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder Completed NCT00340704 Phase 2 tamsulosin hydrochloride
31 Self Management in Urinary Catheter Users Completed NCT00883220 Phase 2
32 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
33 Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
34 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder Enrolling by invitation NCT02582151 Phase 2
35 Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury Not yet recruiting NCT03187795 Phase 2 Oxybutynin Chloride IR;Mirabegron
36 Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury Terminated NCT00512148 Phase 2
37 Augmentation Cystoplasty Using an Autologous Neo-Bladder Terminated NCT00419120 Phase 2
38 Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344) Terminated NCT00711087 Phase 2 BOTOX-A
39 NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder Terminated NCT00213577 Phase 2 type A botulinum toxin
40 Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Terminated NCT01598103 Phase 2 SAF312;Placebo to SAF312
41 Bacteriuria Eradication Through Probiotics Unknown status NCT00717600 Phase 1
42 Colonizing Neurogenic Bladders With Benign Flora Completed NCT00371631 Phase 1
43 Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution Completed NCT01429090 Phase 1 Vagantin®;methantheline solution
44 E. Coli for Prevention of Catheter UTI in SCI Patients Completed NCT00458471 Phase 1
45 Urological Physical Therapy in HTLV-1 With Urinary Symptoms Unknown status NCT01651819
46 Gene Expression in the Overactive Bladder in Children Unknown status NCT02086058
47 Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy Unknown status NCT02059798
48 Sterile Single-use vs Reused Polyvinylchloride Catheter For Intermittent Catheterization In Neurogenic Bladder Completed NCT03424499
49 Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Completed NCT01299792
50 Medico-economical Impact of the Brindley Neurosurgical Technique in France Completed NCT00221767

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 28

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

38
Spinal Cord, Prostate, Testes, Kidney, Colon, Brain, T Cells

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 654)
# Title Authors Year
1
Re: Quality of Life after Suprapubic Catheter Placement in Patients with Neurogenic Bladder Conditions. ( 29310196 )
2018
2
Characterization and in vivo efficacy of a heptapeptide ODT formulation for the treatment of neurogenic bladder dysfunction. ( 29195918 )
2018
3
Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson's disease and multiple system atrophy. ( 29356135 )
2018
4
Pharmacotherapy for Pediatric Neurogenic Bladder. ( 28712052 )
2017
5
Diagnosis and clinical evaluation of neurogenic bladder. ( 29072046 )
2017
6
Management of urinary tract infection with intravesical amikacin may increase the risk of bladder oxidative stress in children with neurogenic bladder. ( 28956280 )
2017
7
What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? ( 28623162 )
2017
8
Management of vesicoureteral reflux in neurogenic bladder. ( 28612061 )
2017
9
Emergency Department Utilization in Patients With Neurogenic Bladder: Contemporary Burden and National Trends in Prevalence, Inpatient Admission, and Associated Charges, 2006-2011. ( 28755964 )
2017
10
Efficacy of holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction (BOO) and non-neurogenic bladder dysfunction. ( 28865604 )
2017
11
Neurogenic Bladder in a Girl After Surgery for Cloacal Malformation: A Case for Bladder Augmentation. ( 28888815 )
2017
12
Long-Term Complications of the Neurogenic Bladder. ( 28716317 )
2017
13
Results of a prospective randomized control trial comparing hydrophilic to uncoated catheters in children with neurogenic bladder. ( 28713004 )
2017
14
Afferent Pathway-Mediated Effect of I+1 Adrenergic Antagonist, Tamsulosin, on the Neurogenic Bladder After Spinal Cord Injury. ( 28954467 )
2017
15
Real world treatment patterns in the neurogenic bladder population: a systematic literature review. ( 29354507 )
2017
16
Home Urodynamic Pressures and Volume Measurement for the Neurogenic Bladder: Initial Validation Study. ( 28587917 )
2017
17
The neurogenic bladder and the physiatrist. ( 29099163 )
2017
18
The Neurogenic Bladder Symptom Score (NBSS): a secondary assessment of its validity, reliability among people with a spinal cord injury. ( 29184133 )
2017
19
A proposal of a follow-up protocol for children with neurogenic bladder. ( 29181965 )
2017
20
Application of data mining techniques to explore predictors of upper urinary tract damage in patients with neurogenic bladder. ( 28832768 )
2017
21
Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. ( 29382457 )
2017
22
Follow-up urodynamics in patients with neurogenic bladder. ( 29021649 )
2017
23
Case Presentation: Neurogenic Bladder in a Girl After Surgery for Cloacal Malformation. ( 28753841 )
2017
24
Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder. ( 28566149 )
2017
25
Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder: A systematic review. ( 28926124 )
2017
26
Re: Barriers to Transition in Young Adults with Neurogenic Bladder. ( 29144923 )
2017
27
Diagnostic value of ultrasonography in spinal abnormalities among children with neurogenic bladder. ( 28848632 )
2017
28
Chronic Renal Failure Secondary to Unrecognized Neurogenic Bladder in A Child with Myelodysplasia. ( 28698733 )
2017
29
Mending Gaps in Knowledge: Collaborations in Neurogenic Bladder Research. ( 28716329 )
2017
30
Correlating spinal cord injuries with neurogenic bladder pathophysiology. ( 28090756 )
2017
31
Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. ( 29168217 )
2017
32
Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions. ( 28761863 )
2017
33
Comment on "neurogenic bladder in a girl after surgery for cloacal malformation". ( 28753873 )
2017
34
Sigmoidocolocystoplasty for neurogenic bladder reviewed after 20 years. ( 29223546 )
2017
35
Role of gentamicin in reducing urinary tract infections in patients with neurogenic bladder. ( 29257743 )
2017
36
Reconstruction of bladder function and prevention of renal deterioration by means of end-to-side neurorrhaphy in rats with neurogenic bladder. ( 29160569 )
2017
37
Is Neurogenic Bladder a Risk Factor for Febrile Urinary Tract Infection After Ureteroscopy and, if so, Why? ( 29056577 )
2017
38
The management of paediatric neurogenic bladder: an approach in a resource-poor setting. ( 28714784 )
2017
39
Applicability of botulinum toxin type A in paediatric neurogenic bladder management. ( 27748667 )
2017
40
A pilot study of the responsiveness of the Neurogenic Bladder Symptom Score (NBSS). ( 29257742 )
2017
41
Identifying Patients with High-Risk Neurogenic Bladder: Beyond Detrusor Leak Point Pressure. ( 28716324 )
2017
42
Urinary tract infection in the neurogenic bladder. ( 26904414 )
2016
43
Neuromodulation in neurogenic bladder. ( 26904417 )
2016
44
Barriers to transition in young adults with neurogenic bladder. ( 27270070 )
2016
45
Remarkable Points for Urodynamic Studies in Neurogenic Bladder Management. ( 27461447 )
2016
46
Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A. ( 27765580 )
2016
47
Conditional Electrical Stimulation in Animal and Human Models for Neurogenic Bladder: Working Toward a Neuroprosthesis. ( 27920880 )
2016
48
Congenital causes of neurogenic bladder and the transition to adult care. ( 26904411 )
2016
49
Sacral nerve stimulation for neurogenic bladder. ( 26960284 )
2016
50
Management of neurogenic bladder in patients with multiple sclerosis. ( 27030526 )
2016

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EBF3 NM_001005463.2(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 GRCh37 Chromosome 10, 131755564: 131755564

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.19 CHRM2 ERBB3 P2RX1 P2RX2
2 10.6 CHRM2 PIP5K1C

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.16 P2RX1 P2RX2
2 postsynaptic membrane GO:0045211 9.13 CHRM2 P2RX1 TRPV1
3 integral component of nuclear inner membrane GO:0005639 8.62 P2RX1 P2RX2

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of smooth muscle contraction GO:0006940 9.37 CHRM2 P2RX1
2 response to ATP GO:0033198 9.32 P2RX1 P2RX2
3 behavioral response to pain GO:0048266 9.26 P2RX2 TRPV1
4 purinergic nucleotide receptor signaling pathway GO:0035590 9.16 P2RX1 P2RX2
5 excitatory postsynaptic potential GO:0060079 9.13 P2RX1 P2RX2 TRPV1
6 urinary bladder smooth muscle contraction GO:0014832 8.62 P2RX2 TRPV1

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.33 P2RX1 P2RX2 TRPV1
2 ligand-gated ion channel activity GO:0015276 9.32 P2RX2 TRPV1
3 cation channel activity GO:0005261 9.26 P2RX1 TRPV1
4 extracellularly ATP-gated cation channel activity GO:0004931 8.96 P2RX1 P2RX2
5 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX1 P2RX2

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....